📰 Project Bioshield News
Page 3 - Project Bioshield News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Project Bioshield. Real-time updates on events, politics, business and more.
December 1, 2023
HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on...
November 30, 2023
Pipeline Expansion of Novel Innate Defense Regulator Technology PRINCETON, N.J., Nov. 30, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and...
November 17, 2023
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
November 17, 2023
PRINCETON, N.J., Nov. 17, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an...
November 15, 2023
The House unanimously passed several amendments to an appropriations bill on Tuesday restricting funding to gain-of-function research and slashing the NIH budget.
November 13, 2023
PRINCETON, N.J., Nov. 13, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an...
October 20, 2023
PRINCETON, N.J., Oct. 20, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an...
October 20, 2023
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
October 16, 2023
PRINCETON, N.J., Oct. 16, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an...
September 27, 2023
SpectralAI has already landed $130 million in government contracts for its artificial intelligence wound care assessment technology.